Di seguito l'elenco completo dei nostri comunicati stampa (pagina 8 di 28):
Conduit partners with SARBORG to integrate AI and cybernetics, boosting efficiency in drug discovery and trials.
FLOW trial shows Ozempic® cuts CKD progression, cardiovascular risks, and mortality, earning EMA's CHMP approval.
Zentalis Pharmaceuticals appoints Wendy Chang as Chief People Officer and Haibo Wang as Chief Business Officer to drive innovation in cancer therapies.
Amar Urhekar takes over as CEO of Avalere Health, aiming to drive innovation in healthcare solutions
Keros holds high-dose TROPOS trial arms due to safety review; 1.5 mg/kg dosing continues, data in Q2 2025.
Medicus Pharma receives FDA MUMS status for D-MNA to treat horse cancer, granting 7-year exclusivity.
IBRANCE® boosts progression-free survival by 15+ months in HR+/HER2+ metastatic breast cancer, per Phase 3 PATINA trial at SABCS 2024.
Ascendis Pharma's sBLA for TransCon hGH in adult GHD was accepted by the FDA, with a decision due July 2025.
ARS Pharma's neffy nasal spray sees approval filings in China, Japan, and Australia after U.S. and EU success.
Takeda highlights its late-stage pipeline, featuring breakthrough therapies and key Phase 3 data expected in 2025.
Novo Nordisk finalises plans to acquire three Catalent sites, prioritising strategic investments over buybacks in 2025.
Glenmark debuts Lacosamide Oral Solution, generic for Vimpat®, growing its U.S. portfolio with 201 approved products.
CHMP recommends advancing affordable healthcare access, including Celltrion’s biosimilars, Eydenzelt, Stoboclo, Osenvelt, and Avtozma.
SK plasma partners with Janssen Korea to distribute Velcade, bolstering its portfolio of cancer treatment options.
Novo Nordisk invests DKK 8.5B in a sustainable Odense facility, creating 400 jobs and advancing rare disease treatments by 2027.
GSK’s Jemperli gets FDA Breakthrough Designation for rectal cancer, showing 100% clinical response in 42 patients.
Thermal Energy inks $2.8M deal with pharma leader, enhancing efficiency and cutting emissions by 728 tons annually.
Reviva’s brilaroxazine shows sustained efficacy, strong safety, and tolerability in 1-year Phase 3 schizophrenia trial.
Merck’s KEYTRUDA is approved in China for stage II-IIIB NSCLC, combining chemo pre-surgery and monotherapy post-surgery.
Foghorn Therapeutics stops independent development of FHD-286 in AML; prioritises pipeline and Lilly collaboration programs.
Xilio Therapeutics names Caroline Hensley as Chief Legal Officer, bringing extensive legal and compliance expertise to the team.
Jazz CEO Bruce Cozadd announces retirement by 2025; Board starts search for a successor as Cozadd remains Board Chair.
GSK'227, a B7-H3-targeted ADC, receives EMA PRIME Designation for treating relapsed extensive-stage SCLC.
Innovent and Lilly expand partnership to distribute and promote Jaypirca® for mantle cell lymphoma in Mainland China.
Single Use Support names Darren Verlenden as CEO to drive global growth and innovation in biopharma solutions.
Jim Scibetta takes the helm as CEO of VectorY Therapeutics, advancing ALS therapy VTx-002 into clinical trials and expanding the company's U.S. presence.
United Therapeutics achieves first living human UKidney transplant, advancing organ supply through genetic engineering.
Tonix's TNX-102 SL receives FDA acceptance for fibromyalgia treatment, backed by positive Phase 3 trial results.
Merck's clesrovimab aims to protect infants from RSV; FDA decision expected by June 2025 after positive trial data.
Evergen, formerly RTI Surgical, advances as a CDMO pioneer, offering allograft and xenograft biomaterials at scale.
Portage Biotech signs a letter of intent with Immunova for potential acquisition of iOx Therapeutics, advancing PORT-2 development.
Regeneron’s EYLEA HD shows non-inferior results in RVO treatment; FDA submission is planned for early 2025.
EVA Pharma's insulin glargine gets Egyptian Drug Authority approval, advancing diabetes treatment in underserved regions.
Corvus Pharmaceuticals will announce Phase 1 results for soquelitinib in atopic dermatitis on December 18, 2024.
Marker Therapeutics receives a $9.5M CPRIT grant to advance MT-601 for metastatic pancreatic cancer, and clinical trials are set for 2025.
Dr. Marc Damelin joins Alphina as CSO, bringing expertise to advance its NAMPT inhibitor targeting solid tumors.
Russia’s mRNA cancer vaccine, set for 2025, shows early success in tumor suppression and metastasis reduction.
Borosil Renewables plans ₹675-crore Indian expansion, ₹700-crore fundraising, and adjusts German operations amid challenges.
Merck partners with Hansoh Pharma, securing global rights to HS-10535 for cardiometabolic advancements and therapies.
Silo Pharma initiates a study on SP-26, a ketamine-based injectable implant targeting chronic pain and fibromyalgia treatment.
Agios' mitapivat receives orphan designation in the EU for sickle cell disease, promising innovative treatment options.
Corvus shares interim data showing soquelitinib's safety and efficacy in treating moderate atopic dermatitis.
MetaVia's DA-1241 significantly reduces ALT, HbA1c, and CAP levels in the Phase 2a trial for MASH, showing strong potential.
Nxera Pharma and Shionogi launch QUVIVIQ™ in Japan, offering a new treatment for insomnia relief in adults.
Prasinezumab shows potential in slowing Parkinson's progression, with further analysis and trials ongoing.
Adicet Bio appoints Dr. Julie Maltzman as Chief Medical Officer, advancing its pipeline in oncology and autoimmune diseases.
CPHI & PMEC India 2024 concluded with record-breaking attendance, highlighting cutting-edge pharma innovations.
Macron and WHO launch the WHO Academy in Lyon to train health leaders and address the global healthcare workforce gap.
Shuttle Pharma partners with UCSF to develop PSMA-B, a theranostic agent redefining prostate cancer care and treatment.
MT-601 by Marker Therapeutics achieves 78% response in Phase 1 lymphoma trial, offering hope for relapsed patients.
Hikma secures rights to 17 Takeda brands in MENA, ensuring supply stability and enhancing profitability.
PTC submits vatiquinone NDA to the FDA for treating Friedreich ataxia in children and adults with strong efficacy and safety data.
Vertex reports Phase 2 success for suzetrigine, demonstrating meaningful pain reduction and a strong safety profile in LSR.
Merck’s Phase 3 results confirm DOR/ISL’s efficacy and safety for HIV-1, with plans to present findings and file data.
Lifecore Biomedical partners with Nirsum Labs advance NRS-033, a promising treatment for opioid and alcohol addiction, leveraging sterile injectable expertise.
Neffy, the first FDA-approved epinephrine nasal spray, ensures broad access via Express Scripts’ formularies.
Ascendis Pharma’s YORVIPATH delivers 24-hour PTH exposure for adults with hypoparathyroidism, transforming care.
AIOCD delegation visits AXA & Heilsa plants, applauding commitment to high-quality, affordable medicines in India.
Regeneron’s Phase 2 trials show promising results for Factor XI antibodies with strong safety profiles in anticoagulant treatment.
Xilio shares plans to present Phase 2 vilastobart data in MSS CRC at ASCO GI 2025, highlighting treatment progress
Merck secures global rights for LM-299 with LaNova Medicines, investing $588M upfront and $2.7B in milestones.
GSK’s phase III trial finds that the Zejula and Jemperli combo boosts Progression-Free Survival in advanced ovarian cancer; safety aligns with expectations.
BioAtla secures $9.2M via direct offering to fund clinical trials for TCE and ADC therapies in solid tumours.
Hikma introduces Indomethacin Suppositories (50mg) in the US for arthritis, gout, and acute painful shoulder.
Novo Nordisk’s REDEFINE 1 trial finds CagriSema achieves significant weight loss and is well-tolerated in obesity treatment.
Organon Korea's Oh So-yun assumes Country Lead role in Malaysia, advancing growth in women's health and chronic care.
VaxCell-Bio collaborates with Bio Design Lab to advance CAR-NK cell therapies, offering safer and cost-effective solutions.
GI Innovation launches a phase 1 trial for GI-102, a subcutaneous immune-oncology drug targeting melanoma.
SK Bioscience partners with Sanofi on next-gen pneumococcal vaccines, targeting children, adults, and unmet global needs.
Celltrion secures Korean approval for Avtozma, its Actemra biosimilar, expanding its interleukin inhibitor portfolio.
RAPT acquires rights to RPT904, a long-acting IgE antibody, promising enhanced allergy treatment with global reach.
The WHO calls for greener pharmaceutical practices, urging sustainability in manufacturing, packaging, and distribution.
AstraZeneca’s Tagrisso is approved in the EU for treating advanced NSCLC with EGFR mutations post-CRT
Tonix's TNX-102 SL, a non-opioid for fibromyalgia, nears FDA approval with promising Phase 3 trial results.
Sanofi and SK Bioscience collaborate on next-gen pneumococcal vaccines, including PCV21, now in phase 3 trials
Luxembourg pledges €47.5M to WHO for health crises, equity, and SDG goals, marking a historic collaboration.
Porton and Dragon Sail join forces to revolutionize ADC development and accelerate drug availability worldwide.
Arrowhead launches clinical trials for ARO-INHBE, an RNAi obesity treatment, with ARO-ALK7 also progressing
GEMTESA earns FDA approval as the first β3 agonist for men with OAB symptoms linked to BPH, now available in the U.S.
OBI Pharma and GlyTech collaborate to advance ADC development, focusing on glycan production and cancer therapies.
AstraZeneca and Daiichi Sankyo withdraw EU application for datopotamab deruxtecan but affirm their commitment to progress.
Enanta Pharmaceuticals will appeal a court ruling favoring Pfizer in a patent dispute over COVID-19 antiviral Paxlovid.
Prothix LifeSciences partners with Oviya MedSafe to redefine global drug safety, clinical trials, and regulatory compliance.
Bio-Thera and Tabuk collaborate to bring BAT2206, a Stelara biosimilar, to Saudi Arabia, boosting healthcare accessibility.
Meiji Seika Pharma establishes Taiwan subsidiary, boosting healthcare solutions with REZUROCK and key therapies in Asia.
JR-441, JCR’s therapy for MPS IIIA, gains orphan drug status in Japan, bolstering global efforts for rare disease treatments.
MedMira’s Multiplo® TP/HIV test gains Health Canada approval, providing rapid, dual HIV/syphilis detection nationwide.
Qilu's QLS32015 demonstrates remarkable tumor response and tolerability in Phase I trials for relapsed multiple myeloma.
KIST's peptide-based eye drops for dry AMD reduce retinal degeneration, enhancing safety and patient adherence.
Phase 3 trial reveals gecacitinib's superior spleen reduction, symptom relief, and safety in myelofibrosis patients.
ENCell's new CDMO contract with a pharma leader highlights its GMP-certified excellence in biopharma production.
Axcelead and Astellas unite to leverage the DegLead™ Platform, driving innovation in targeted protein degradation.
Hikma debuts generic Liraglutide, a GLP-1 diabetes treatment, expanding affordable care for adults and children.
Elite Pharmaceuticals introduces a cost-effective generic Vyvanse® for ADHD, offering patients greater accessibility.
Kwality Pharmaceuticals achieves SAHPRA approval for Tamoxifen, advancing quality oncology treatment in South Africa.
Mankind Pharma collaborates with Innovent Biologics to introduce sintilimab, revolutionizing cancer treatment in India.
IDEAYA licenses SHR-4849 from Hengrui Pharma to advance treatment for DLL3-expressing solid tumors like SCLC and NETs.
Hikma's ePHEDrine Sulfate Injection in prefilled syringes treats anesthesia-related hypotension, enhancing care access.
RenovaroCube names Maurice van Tilburg CEO, driving AI-powered cancer diagnostics and multi-omics solutions.
reace launches Percuplasty™, a percutaneous system offering 3D bunion correction with smaller incisions, less pain, and quicker recovery.
Japan approves VYVDURA, a subcutaneous CIDP therapy enabled by Halozyme’s ENHANZE®, for at-home patient convenience.
Radiopharm partners with Lantheus to advance clinical development of Lantheus innovative radiopharmaceuticals in Australia targeting solid tumours.
Autonomix secures key patents for its precision nerve ablation tech, aiming to ease pain and explore cancer treatment potential.
FDA approves Opdivo Qvantig™ co-formulated with Halozyme’s ENHANZE®, offering faster subcutaneous administration and similar efficacy to IV Opdivo.
Polyrizon secures patents for C&C™ and T&T™ platforms, innovating nasal protection and effective drug delivery systems.
Chimerix submits NDA for dordaviprone in treating recurrent H3 K27M-mutant glioma, seeks priority review, and secures up to $30M loan.
Orion and Marinus end the European ganaxolone agreement. Marinus regains commercial rights, and Orion suspends launch preparations.
Axsome’s AXS-05 delays agitation relapse in Alzheimer’s, achieves key endpoints in Phase 3 trials, and earns FDA status.
Galera’s acquisition of Nova Pharmaceuticals adds a pan-NOS inhibitor to its pipeline, targeting resistant breast cancers.
Cocrystal Pharma extends its Phase 2a study for CDI-42344 after low H3N2 infection rates. The trial evaluates safety, efficacy, and PK.
Altamira advances RNA delivery with CycloPhore™, achieving strong circular mRNA transfection and protein expression, also filled a patent.
Oncotelic launches PDAOAI for biotech AI document search, enabling precise answers and decentralised governance via PDAO tokens.
ARsgen launches trial for KJ-C2219, an allogeneic CAR T-cell therapy targeting CD19/CD20, in relapsed/refractory B-NHL patients.
Yuhan's lazertinib gains European approval, becoming Korea's first anticancer drug authorized in both the U.S. and Europe for NSCLC.
Huons transitions to a single-CEO structure with Song Soo-young, followed by the resignation of Yoon Sang-bae.
HK inno.N files phase 3 IND for obesity drug IN-B00009, targeting weight loss and safety in a 3-year clinical trial
Handok begins local sales of Lipidil, Abbott's hyperlipidemia drug, strengthening its chronic disease treatment portfolio.
Prag Goel joins Alembic Pharma as VP of Sales and Marketing, bringing 30 years of diverse industry experience.
HOOKIPA and Poolbeg plan all-share merger to form a Nasdaq-listed biopharma focused on cancer and unmet medical needs.
Veeda Group becomes Veeda Lifesciences, marking its growth into a full-spectrum partner in global drug development services.
Radius Pharmaceuticals partners with Pharmanovia to bring abaloparatide, an osteoporosis therapy, to the Asia Pacific region.
ANI Pharmaceuticals introduces Prucalopride Tablets, a generic Motegrity® version, following FDA approval, with a $168M U.S. market value.
Innovent and Roche collaborate on IBI3009, an inventory DLL3 ADC, with $80M upfront and $1B in milestones possible.
Karyopharm names Lori Macomber as CFO, leveraging her 20+ years in life sciences finance to drive growth and innovation.
Capricor completes BLA for deramiocel, a DMD cardiomyopathy therapy backed by Phase 2 data and Orphan Drug Designations.
NervGen enrols the final participant in the chronic cohort of its NVG-291 SCI trial, advancing to subacute screening after IRB approval.
Joseph F. McGuire, named NEXGEL's CFO, brings 30+ years of experience as Adam E. Drapczuk will remain as a consultant.
Scott Coiante was named CFO at Lexicon Pharmaceuticals, with 35 years of finance experience in life sciences, previously at Agile Therapeutics and Aprea.
HOPE Therapeutics acquires Kadima Neuropsychiatry, a leader in interventional psychiatry, to drive advanced treatments for CNS disorders.
Eton Pharmaceuticals acquires Galzin®, enhancing support for Wilson Disease patients with treatment access and global expansion.
Chime Biologics and Mabgeek achieved a significant milestone with MG-K10, an anti-IL-4Rα antibody, entering Phase III trials.
Nona Biosciences announces BeiGene's acquisition of global rights to a DualityBio-developed ADC targeting tumours.
GSK's Nucala wins approval in China as an add-on therapy for adults with uncontrolled CRSwNP, easing key symptoms.
Shilpa Medicare advances to Phase III trials for recombinant albumin, revolutionizing treatment for critical conditions.
Vetter appoints three senior leaders as managing directors, reinforcing global growth and commitment to serving patients worldwide.
Dr. Vellaian Karuppiah joins Acme and Immacule Group as COO, bringing 20+ years of expertise in manufacturing, tech transfer, and operations.
JCR and Modalis advance CNS gene therapy, validating proof of concept and entering pre-clinical studies for minimally invasive treatment
China approves first stem cell therapy for transplant complications and a new long-acting HIV drug needing only two shots a year.
NMD Pharma's NMD670 receives FDA orphan drug status to treat Charcot-Marie-Tooth disease, advancing trials for this rare neuromuscular disorder.
Discover cutting-edge pharma solutions, network with global experts, and unlock new business opportunities.
EMA backs Acurx's ibezapolstat Phase 3 trials, focusing on treating CDI and reducing recurrence in global patient populations.
Perspective Therapeutics appoints Juan Graham as CFO. He brings 25 years of finance leadership from FibroGen and Johnson & Johnson.
Tempest Therapeutics’ amezalpat receives FDA Orphan Drug Designation after showing survival benefits in liver cancer trials.
Portage Biotech re-launches Cyncado Therapeutics, with CEO Peter Molloy driving the development of adenosine receptor antagonists for cancer.
ARS Pharma seeks approval for neffy in Canada and UK while advancing global licensing and clinical trials for new indications.
RAPT Therapeutics appoints Lori Lyons-Williams as board chair. Industry veteran succeeds William Rieflin, now a company consultant.
Elutia collaborates with Vizient to offer EluPro™ BioEnvelope to S3P's 993 acute care facilities, providing innovative solutions for post-surgical care.
ImmunityBio secures permanent J-code for ANKTIVA, streamlining access for bladder cancer patients and providers with broad coverage.
Dan Monahan joins Amylyx as Chief Commercial Officer, driving commercialisation and avexitide’s launch for PBH treatment.
Variant Bio joins Novo Nordisk in a $50M genomics venture to develop innovative treatments for metabolic diseases globally.
Recursion advances REC-3565 for B-cell cancers and REC-4539 for SCLC, with regulatory clearances from MHRA & FDA for Phase 1 trials.
Canyon Labs strengthens services with iuvo acquisition, focusing on end-to-end medical and pharmaceutical testing solutions.
Gain actionable insights at the Pharma Project & Portfolio Management 2025 in Goa, with expert sessions and networking.
Bio-Rad introduces 45 cm Foresight Pro Columns, enhancing downstream purification for vaccines, antibodies, and proteins.
Molex completes acquisition of Vectura, enhancing Phillips Medisize’s expertise in inhalation drug delivery and pharmaceutical R&D.
BioInvent reports a complete and partial response in the NHL trial for BI-1206 combo therapy; melanoma CR is nearing a two-year milestone.
ProBioGen enhances its protein and viral vector production with a new 1000L GMP protein line and advanced viral manufacturing facilities.
Island Pharmaceuticals starts Phase 2b trial for ISLA-101, testing its safety and effectiveness in reducing dengue virus symptoms.
Biomea Fusion shares preclinical data showing improved metabolic markers with icovamenib and semaglutide in diabetes models.
Expanded Novo Nordisk-Valo partnership leverages AI to advance 20 drug programs in cardiometabolic care globally.
Agios' PYRUKYND® gains FDA sNDA acceptance for thalassemia treatment. PDUFA decision set for September 7, 2025.
Merck's GARDASIL became the first HPV vaccine approved for males in China, targeting HPV-related cancers, warts, and precancerous lesions.
Silo Pharma receives USPTO patent approval for SPC-15, enhancing its position in PTSD therapy with intranasal drug delivery.
Tonix appointed Gary Ainsworth as VP of Market Access along with the FDA review of TNX-102 SL for fibromyalgia, a chronic pain condition.
Newron and Myung In Pharm join forces to develop and commercialise evenamide, a novel therapy for treatment-resistant schizophrenia in South Korea.
PrecisionLife appoints Bill Keating as CCO to scale Mechanostic® tests, transforming chronic disease diagnostics globally.
Catalyst resolves litigation with Teva, delaying FIRDAPSE generic launch to 2035, ensuring patient access and IP protection.
WHO's new G6PD test helps prevent complications from malaria treatments, ensuring safer care for P. vivax patients.
Evonik and ST Pharm collaborate to enhance RNA and nucleic acid therapies, speeding up treatment development.
Aspyre Lung by Biofidelity and CellCarta enhances NSCLC biomarker detection, accelerating clinical trial enrollment globally.
Jo Marshall joins Coronado as EVP of Data Services, leveraging expertise to enhance drug development and patient safety.
Zentalis secures FDA Fast Track Designation for azenosertib, targeting platinum-resistant ovarian & PROC cancers tied to Cyclin E1.
Bora Biologics partners with DotBio to accelerate DB007, a tri-specific antibody, through advanced manufacturing and development.
Seres' SER-155 data reveal improved gut barrier integrity, reduced bloodstream infections, and enhanced immune balance in allo-HSCT patients.
GSK’s Shingrix prefilled syringe application is accepted by the FDA, offering a more convenient shingles vaccination option for healthcare providers.
Rigel’s R289 granted FDA Orphan Drug Designation, boosting its development for lower-risk myelodysplastic syndromes treatment.
UCB collaborates with XtalPi, using AI-driven XtalFold™ to accelerate antibody design and biologics innovation.
Genenta and AGC Biologics expand manufacturing capacity for Temferon, supporting GBM and metastatic cancer clinical trials.
Telix expands pipeline and innovation with ImaginAb's biologics platform and radiopharmaceutical technology.
Ascendis Pharma outlines 2025 goals, introduces the new TransCon platform, and reports substantial 2024 revenues at the J.P. Morgan Conference.
Telix reclaims Scintimun to enhance diagnostic use, sales, and clinical applications for unmet medical needs.
NMPA approves Sarclisa for relapsed multiple myeloma, offering innovative treatment options in China.
PM Modi praises the completion of the Indian Genome Project, which will boost healthcare and precision medicine through genetic mapping of India’s population.
Merus and Biohaven join forces to co-develop bispecific ADCs, combining platforms to transform cancer therapy.
Caribou initiates the GALLOP Phase 1 trial for lupus, advancing CAR-T therapy programs with key 2025 data milestones.
Molecular Partners and Orano Med expand collaboration to create innovative targeted alpha radiotherapies for cancer.
AbbVie partners with Simcere Zaiming to develop SIM0500, a trispecific antibody targeting multiple myeloma.
Updates on ABBV-RGX-314 clinical programs: advancing gene therapy for wet AMD and diabetic retinopathy.
Tarsus targets ocular rosacea with TP-04, boosts XDEMVY growth, and advances global initiatives for transformative eye care.
ORIC shares 2024 achievements, including Phase 1b data for ORIC-944 and key milestones for oncology advancements.
Regeneron and Truveta announce the Truveta Genome Project, aiming to sequence 10 million genomes to transform genetic research and healthcare delivery.
Interim data from Corvus Pharmaceuticals’ Phase 1 trial of soquelitinib demonstrate safety and significant efficacy in treating moderate-to-severe atopic dermatitis.
GSK acquires IDRx for $1 billion upfront, gaining IDRX-42, a precision therapeutic targeting primary and secondary KIT mutations in GIST.
ORIC Pharmaceuticals to initiate a Phase 1b trial of ORIC-114 and SC amivantamab for first-line treatment of advanced NSCLC with EGFR exon 20 insertion mutations, starting Q1 2025.
Salarius Pharmaceuticals merges with Decoy Therapeutics to advance Decoy's peptide conjugate therapeutics pipeline, targeting respiratory infectious diseases and oncology.
Astria Therapeutics' ALPHA-ORBIT Phase 3 trial of navenibart for hereditary angioedema to evaluate Q3M and Q6M dosing, aiming for global registration and patient-centric treatment options.
Context Therapeutics announces Andy Pasternak as Chairman of its Board, bringing decades of expertise to drive innovation in T cell engagers for solid tumor treatment.
Elutia introduces EluPro™, the first FDA-cleared biomatrix to prevent infections in implantable devices.
Serina Therapeutics appoints Karen J. Wilson to its Board, enhancing leadership for transformative biotech growth.
AskBio’s Phase II gene therapy trial for Parkinson’s disease begins participant randomization, advancing AB-1005 research.